Skip to content

Voices Of Individuals: Challenges and Experiences Of bvFTD

VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences Of bvFTD]

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04060082
Enrollment
26
Registered
2019-08-16
Start date
2019-06-26
Completion date
2025-12-31
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal Degeneration, Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, FTD

Keywords

FTD, Interview, Genetics, Persons diagnosed, Frontotemporal degeneration, bvFTD, Chromosome 9 open reading frame 72 (C9ORF72), Microtubule-associated protein tau (MAPT), Progranulin (GRN), TAR DNA-binding protein (TARDBP), Valosin-Containing Protein (VCP), Charged multivesicular body protein 2B (CHMP2B)

Brief summary

The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD). The study aims to understand how bvFTD impacts individuals' day to day lives, how people think about themselves, and what challenges they face.

Detailed description

The VOICE Of bvFTD study is a study being conducted at the University of Pennsylvania. The study was developed and initiated in collaboration with the Johns Hopkins Bloomberg School of Public Health and the National Human Genome Research Institute. The goal of this study is to learn more about what it is like to live with or at high risk of developing behavioral variant frontotemporal dementia (bvFTD). The study will involve telephone interviews to help learn as much as possible about living with bvFTD. The hope is that this will guide future research, resource development, and clinical practice. Participants will have at least two phone calls from the study team. During the initial phone call, which will take about 15 to 20 minutes, the participant will be asked some basic questions about demographics and the study details will be reviewed as part of the consent process. During another call the participant will be asked some questions to assess his or her thinking, and will complete the interview which will last about 30 to 60 minutes. There are no physical or medical procedures included in this study. The consent process, screening, interview scheduling, and the interview itself will take place over two or three phone calls, which may occur over several weeks. A person may be able to take part in this study if they are a person with bvFTD, or if they have been found to have a genetic change that causes bvFTD.

Interventions

OTHERTelephone Interview

Participants will be asked to answer questions about their experiences with FTD.

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * Speak fluent English * People with bvFTD must have been diagnosed with behavioral variant frontotemporal degeneration (bvFTD) * People with a known genetic risk factor for bvFTD must have an identified disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family * The diagnosis or genetic testing results must have been disclosed to the participant at least two months prior to study enrollment

Exclusion criteria

* Inability to complete the informed consent comprehension process * Under 18 years of age * Does not speak English * Received diagnosis or testing result less than two months prior to study enrollment

Design outcomes

Primary

MeasureTime frameDescription
Affective and Behavioral ResponsesThrough study completion: about 1.5-2 hours total over several weeksHow participants describe and categorize their emotional reactions to receiving a diagnosis of bvFTD or positive genetic testing result, and their experiences living with that knowledge. It will also explore how patients describe their behavior in response to the testing or diagnosis, such as use of coping strategies, challenges faced, and decisions to disclose their status to family and friends.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026